These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7711671)

  • 1. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
    Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
    Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for the treatment of chronic graft-versus-host disease.
    Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
    N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
    Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
    Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide responsive chronic pulmonary GVHD.
    Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA
    Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide for treatment of graft-versus-host disease.
    Vogelsang GB; Hess AD; Santos GW
    Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
    Nair V; Sharma A; Ghosh I; Arora S; Sahai K; Dutta V
    J Assoc Physicians India; 2005 Nov; 53():988-90. PubMed ID: 16515241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.
    Gillio AP; Boulad F; Small TN; Kernan NA; Reyes B; Childs BH; Brochstein JA; Laver J; Castro-Malaspina H; O'Reilly RJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):18-24. PubMed ID: 9209737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features in patients with hepatic graft-versus-host disease.
    Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
    Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful renal transplantation following prior bone marrow transplantation in pediatric patients.
    Thomas SE; Hutchinson RJ; DebRoy M; Magee JC
    Pediatr Transplant; 2004 Oct; 8(5):507-12. PubMed ID: 15367289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Photochemotherapy (PUVA) of acute graft-versus-host disease].
    Reinauer S; Lehmann P; Plewig G; Heyll A; Söhngen D; Hölzle E
    Hautarzt; 1993 Nov; 44(11):708-12. PubMed ID: 8276589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
    Tolland JP; Devereux C; Jones FC; Bingham EA
    Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.